C-Reveal Therapeutics

C-Reveal Therapeutics

Testing the Waters
Early Stage

C-Reveal’s proprietary technology helps the body’s natural immune system to identify and kill cancer cells.

C-Reveal’s proprietary technology helps the body’s natural immune system to identify and kill cancer cells.

Overview

Raised to Date: Raised: $0

Total Commitments ($USD)

Platform

Netcapital

Start Date

12/17/2020

Close Date

Testing the Waters

Min. Goal
Funded
Max. Goal
Funded
Min. Investment

$100

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

Test the Waters / RegD 506(c)    Open SEC Filing

Price Per Share

$10.00

Pre-Money Valuation

$10,000,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

01/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$0

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

High

Capital Intensity

High

Location

Pembroke, Massachusetts

Business Type

Growth

Company Website

C-Reveal Therapeutics, with a pre-money valuation of $10 million, is Testing the Waters on NetCapital. The company has identified 2 key cancer-specific enzymes that, when inhibited, reveal hidden tumors to the immune system. C-Reveal plans to develop inhibitors for these enzymes, which will allow the immune system to recognize, target, and attack cancer cells. They will also allow existing cancer immunotherapies to work in a greater number of patients. The company was founded by Thomas Haag, Ph.D, J.D., Mark Cobbold, M.D., Ph.D., Keith Flaherty, M.D. and Cyril Benes, Ph.D. C-Reveal is partnering with Evotec, a European-based contract research organization for the next step in our drug discovery process.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
C-Reveal Therapeutics 04/29/2021 Netcapital $10,000,000 $1,346,500 Equity - Common Funded RegCF / RegD 506(c)
C-Reveal Therapeutics 01/26/2021 Netcapital $10,000,000 $0 Equity - Common Funded Test the Waters / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
C-Reveal Therapeutics on Netcapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $10,000,000
Price per Share: $10.00

Follow company

Follow C-Reveal Therapeutics on Netcapital
View on Netcapital (Testing the Waters)
Deal Analytics
Deal Considerations

Buy C-Reveal Therapeutics's Deal Report

Warning: according to the close date for this deal, C-Reveal Therapeutics may no longer be accepting investments.

C-Reveal Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on C-Reveal Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether C-Reveal Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the C-Reveal Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge